Results 121 to 130 of about 796 (164)

Cenobamate for the treatment of focal epilepsies

Expert Opinion on Pharmacotherapy, 2020
Antiseizure drugs (ASDs) play a central and crucial role in the treatment of epilepsy patients because the majority require anticonvulsant treatment for an extended period of time. Due to the fact that 30% of patients are refractory to medical treatment, new therapeutic options are necessary.
Adam Strzelczyk, Catrin Mann, Laurent M. Willems, Felix Rosenow, Sebastian Bauer   +4 more
openaire   +2 more sources

Cenobamate (Xcopri)

Canadian Journal of Health Technologies, 2023
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire   +1 more source

Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug‐resistant focal seizures [PDF]

Epilepsia Open
Antiseizure medication; Cenobamate; EpilepsyMedicación anticonvulsiva; Cenobamato; EpilepsiaMedicació anticonvulsiva; Cenobamat; EpilèpsiaObjective Cenobamate is an antiseizure medication (ASM) associated with high rates of seizure freedom and ...
Mar Carreño, Antonio Gil-Nagel, Manuel Toledo   +2 more
exaly   +2 more sources

Cenobamate for the treatment of focal epilepsy

Drugs of Today, 2020
Focal-onset or partial seizures are localized to a specific brain area or areas of the cerebral hemisphere. Cenobamate (CNB, Xcopri, YKP-3089; SK Life Science) is a recent U.S. Food and Drug Administration (FDA)-approved drug for the treatment of focal-onset seizures in the adult population.
openaire   +2 more sources

Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy

Epilepsy Research, 2023
Cenobamate was approved by the US Food and Drug Administration (FDA) based on studies of adjunctive therapy in patients with focal epilepsy. To support the use of cenobamate monotherapy, this pharmacokinetic (PK)-based simulation analysis evaluated the predicted PK exposure of cenobamate when used as monotherapy versus adjunctive therapy.A population ...
Vijay, Vashi, William E, Rosenfeld, Louis, Ferrari, Marc, Kamin   +3 more
openaire   +2 more sources

Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug

Neurochemical Research, 2020
Central nervous system (CNS) injuries annually afflict approximately 2.7 million people in United States only, inflicting costs of nearly 100 billion US dollars. The gravity of this problem is a consequence of severe and prolonged disability of patients due to a scarce regeneration of CNS, along with the lack of efficient neuroprotective and ...
Michał Wiciński, Oskar Puk, Bartosz Malinowski   +2 more
openaire   +2 more sources

Cenobamate for focal seizures — a game changer?

Nature Reviews Neurology, 2020
In the first published efficacy study of cenobamate for treatment-resistant focal seizures, high doses produced high seizure-free rates, suggesting cenobamate can outperform existing options. A risk of serious rash and low tolerability at higher doses means further safety studies and clinical experience are needed to determine its clinical value.
openaire   +2 more sources

The cenobamate KORK study—A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add‐on lacosamide, perampanel, and brivaracetam

Epilepsia Open
Objective In Europe, cenobamate has been approved for use as an adjunctive therapy in adult patients with epilepsy (PWE) with focal‐onset seizures (FOS) who have not responded satisfactorily to treatment with at least two antiseizure medications (ASMs ...
Bernhard J Steinhoff, Tassanai Intravooth   +1 more
exaly   +2 more sources

Cenobamate Plasma Levels in Patients with Epilepsy: Correlation with Efficacy and Tolerability?

Journal of Clinical Medicine
Objective: Cenobamate is approved by the European Medicine Agency for the treatment of adult patients with epilepsy (PWEs) with ongoing focal-onset seizures despite appropriate treatment with at least two established antiseizure medications.
Bernhard J Steinhoff, Tassanai Intravooth, Steinhoff Bernhard J   +2 more
exaly   +2 more sources

Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy

Epilepsia Open
Objective: Cenobamate is a recently approved antiseizure medication that proved to be safe and effective in randomized controlled trials. However, little is known about its impact on some areas frequently affected by epilepsy.
Judit Catalán-Aguilar, Kevin G Hampel, Irène Cano-Lopez   +2 more
exaly   +2 more sources